Ascendis Pharma (ASND): Three New Drugs Are Turning This Biotech Into A Growth Machine

Ascendis Pharma (ASND) reported Q2 2026 revenue of EUR 315 million, up 105% YoY, driven by its TransCon product portfolio. Key products include YORVIPATH (EUR 252M), SKYTROFA (EUR 55M), and YUVIWEL (EUR 8M). Net profit was EUR 207 million, with cash and equivalents at EUR 812 million. The company expects full-year operating cash flow to exceed EUR 500 million. Management confirmed its EUR 5 billion revenue target by 2030 and highlighted ongoing clinical trials and partnerships.

Vertex (VRTX) agreed to acquire Crinetics (CRNX) for about $10B, or $85.00 per share in all cash, approved by both boards and expected to close in Q3 2026. CRNX shares rose about 99% to ~$83.54. Vertex projects the endocrine franchise could exceed $5B peak annual sales. Peers NBIX and CORT also gained on M&A expectations.

BitFuFu (FUFU) reported a 63% revenue decline to $42.8M in Q2, with net loss of $20.5M, despite a 47% increase in self-mining hashrate and 34% more Bitcoin produced. Cloud mining revenue dropped 73.6%, and self-mining revenue fell slightly. Shares fell 11% post-earnings.

Zim reported Q2 revenue of $1.78 billion and reaffirmed its 2026 guidance for adjusted EBITDA of $2 billion to $2.4 billion and adjusted EBIT of $700 million to $1.1 billion. The company expects to pay a dividend based on 2026 results. The proposed merger with Hapag-Lloyd is pending regulatory approvals, despite opposition from Israeli agencies.

Ondas (ONDS) reported Q2 revenue of $83.8M, up 67% sequentially and 85% YoY organically. The company raised full-year guidance to $525M-$550M and expects a $1B annualized run rate by year-end. However, it also posted a $51M adjusted EBITDA loss and warned of margin pressure. The stock is polarizing, with high institutional ownership and significant short interest.

H World Group (HTHT) shares rose 11.3% after Q2 results showed 13.2% hotel turnover growth and 10.8% revenue increase. The company raised 2026 revenue growth forecast to 4%-8% and approved a $2.5B return plan. It operates 13,539 hotels with 1.34M rooms and has 3,089 hotels in pipeline. Cash reserves were RMB14.2B against RMB4.2B debt. The board declared a $275M dividend.